376 related articles for article (PubMed ID: 17605004)
1. Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
Lofwall MR; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2007 Oct; 194(3):381-93. PubMed ID: 17605004
[TBL] [Abstract][Full Text] [Related]
2. Physical dependence potential of daily tramadol dosing in humans.
Lanier RK; Lofwall MR; Mintzer MZ; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2010 Sep; 211(4):457-66. PubMed ID: 20589494
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.
Lofwall MR; Babalonis S; Nuzzo PA; Siegel A; Campbell C; Walsh SL
Drug Alcohol Depend; 2013 Nov; 133(1):188-97. PubMed ID: 23755929
[TBL] [Abstract][Full Text] [Related]
4. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
Carroll CP; Walsh SL; Bigelow GE; Strain EC; Preston KL
Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
[TBL] [Abstract][Full Text] [Related]
5. Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers.
Mintzer MZ; Lanier RK; Lofwall MR; Bigelow GE; Strain EC
Drug Alcohol Depend; 2010 Oct; 111(3):265-8. PubMed ID: 20538418
[TBL] [Abstract][Full Text] [Related]
6. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
7. Effects of buprenorphine/naloxone in opioid-dependent humans.
Stoller KB; Bigelow GE; Walsh SL; Strain EC
Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
9. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.
Lofwall MR; Babalonis S; Nuzzo PA; Elayi SC; Walsh SL
Drug Alcohol Depend; 2016 Jul; 164():143-150. PubMed ID: 27234658
[TBL] [Abstract][Full Text] [Related]
10. Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.
Chu LF; Sun J; Clemenson A; Erlendson MJ; Rico T; Cornell E; Obasi H; Sayyid ZN; Encisco EM; Yu J; Gamble JG; Carroll I; Clark JD
J Addict Med; 2017; 11(5):342-349. PubMed ID: 28514235
[TBL] [Abstract][Full Text] [Related]
11. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.
Fudala PJ; Yu E; Macfadden W; Boardman C; Chiang CN
Drug Alcohol Depend; 1998 Mar; 50(1):1-8. PubMed ID: 9589267
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males-a double-blinded, randomized study.
Weisshaar S; Brandt L; Litschauer B; Sheik-Rezaei S; Moser L; Nirnberger G; Kühberger E; Bauer U; Firbas C; Gouya G; Wolzt M; Fischer G
Br J Clin Pharmacol; 2020 Aug; 86(8):1610-1619. PubMed ID: 32145041
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.
Mendelson J; Jones RT; Welm S; Baggott M; Fernandez I; Melby AK; Nath RP
Psychopharmacology (Berl); 1999 Jan; 141(1):37-46. PubMed ID: 9952063
[TBL] [Abstract][Full Text] [Related]
14. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer.
Sykes NP
Palliat Med; 1996 Apr; 10(2):135-44. PubMed ID: 8800821
[TBL] [Abstract][Full Text] [Related]
15. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.
Dunn KE; Weerts EM; Huhn AS; Schroeder JR; Tompkins DA; Bigelow GE; Strain EC
Addict Biol; 2020 Jan; 25(1):e12680. PubMed ID: 30295400
[TBL] [Abstract][Full Text] [Related]
16. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Bhateja P; Singh TG; Singh N
Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
Walsh SL; Strain EC; Bigelow GE
Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
Lamas X; Farre M; Cami J
J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
[TBL] [Abstract][Full Text] [Related]
19. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
[TBL] [Abstract][Full Text] [Related]
20. A small-dose naloxone infusion alleviates nausea and sedation without impacting analgesia via intravenous tramadol.
Jia DL; Ni C; Xu T; Zhang LP; Guo XY
Chin Med J (Engl); 2010 Jul; 123(13):1695-8. PubMed ID: 20819631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
